Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP2 + nivolumab versus ipilimumab + nivolumab in metastatic uveal melanoma
2023-508784-68-00Phase 3Authorised
- Sponsor
- Replimune Group, Inc.
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial in intraocular melanoma comparing RP2 + nivolumab with ipilimumab + nivolumab (2 arms). Primary endpoints: Overall survival and Progression-free survival. Planned start Dec 2025; status: authorised.
02
Drugs
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on 2023-508784-68-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508784-68-00.